Sutro Biopharma Operating Income

As of the most recent data (March 2026), STRO shows a operating income of $-120M. That compares with $-250M in the prior-year period — up 54.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, STRO's operating income is now $-120M (was $-250M) — a 54.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sutro Biopharma is outperforming or lagging.

Tracking STRO's operating income over time shows whether Sutro Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-120M That compares with $-250M in the prior-year period — up 54.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Sutro Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-120M) with ownership activity and broader fundamentals.

Sutro Biopharma's operating income is $-120M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.